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Introduction
Multi-targeted drugs and drug candidates currently in clinical development generally affect related members of the same gene family. Inhibitors of HER family RTKs, including erlotinib, gefitinib, and lapatinib, have become important drugs for treating human solid tumors (1, 2) . However, due to molecular heterogeneity among and within tumors, their efficacy is restricted to a small subset of patients (2) . The efficacy of RTK inhibitors is also limited by drug resistance that frequently emerges following treatment (3, 4) . Several strategies have been proposed to overcome the limited activity of, and acquired resistance to RTK inhibitors. One particularly promising approach involves modulation of RTK pathway signaling by inhibition of HDACs. By modulating the acetylation of both histone and non-histone substrates (5 -8) , HDAC inhibitors can regulate a variety of cell functions through indirect effects on downstream targets.
Importantly, many of these targets are key regulators of RTK signaling pathways (6, 7, 9) . Several studies also suggest a synergy between RTK or conventional chemotherapeutics and HDAC inhibition in cancer cells (10 -14) . The combination of the HDAC inhibitor romidepsin (Gloucester/ Fujisawa) with erlotinib demonstrated increased erlotinib sensitivity with synergistic apoptotic effects in vitro and in xenograft non-small cell lung cancer (NSCLC) tumor models (15) . Synergistic preclinical anti-tumor activity was also observed for the combination of the HDAC inhibitor, PXD101 (Curagen), and erlotinib. In addition, PXD101 treatment resulted in downregulation of Human Epidermal Growth Factor Receptor 3 (HER3) protein levels. HER3 can enable cancer cells to escape the effects of conventional EGFR/HER2 inhibitors (16, 17) . These preclinical study results further suggest the potential benefit of combining HDAC and RTK inhibitors for treatment of cancer patients. Regarding the rationale for increased sensitivity to HER2 inhibition by co-treatment with an HDAC inhibitor, LAQ824 (a cinnamic acid Given that treatment with LAQ824 attenuates the levels and activity of AKT and c-Raf-1, it is therefore possible that resistance to trastuzumab based on HER2-independent increased activity of AKT may be overcome by co-treatment with LAQ824 and trastuzumab (12) .
CUDC-101 (7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy) Nhydroxyheptanamide) is a synthetic small-molecule member of the quinazoline class of compounds with a molecular weight of 434.5 Da. CUDC-101 is a potent inhibitor of EGFR, HER2, class I and class II HDACsand can disrupt signaling downstream of EGFR, HER2, HER3, c-MET, AXL, and AKT (18 -20) .
In preclinical in vitro experiments, CUDC-101 inhibited HDAC activity and EGFR autophosphorylation both with an IC 50 of 4nM. In in vitro mechanistic studies, CUDC-101 reduced MET expression, MET phosphorylation, and inhibited the AKT signaling pathway in MET amplified NSCLC H1993 cells (18) . In vivo, CUDC-101 displayed broad antitumor activity in xenograft tumor models across a wide range of cancer types.
Pharmacodynamic analysis of several human xenograft tumors after CUDC-101 treatment demonstrated: 1) inhibition of HDAC activity (histone acetylation), 2) inhibition of EGFR and HER2 phosphorylation, 3) inhibition of tumor cell proliferation (decrease of Ki67 levels), and 4) induction of apoptosis (Caspase 3 induction) (18) . The therapeutic efficacy in xenograft models is likely due to the improved potency of the kinase inhibitory activities and the synergy achieved by the combined RTK and HDAC inhibitory activity within cancer cells. Additionally, CUDC-101 and single-targeted HDAC inhibitors reduce HIF-1α protein levels, thus suggesting that antitumor activity could also be accomplished by a combination of antiproliferative and antiangiogenic effects (9, 19).
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Materials and Methods

Patients Eligibility
Eligible patients had pathologically confirmed solid tumors refractory to standard therapy or for which no standard therapy existed; age >18 years; life-expectancy >12 weeks; an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2; previous therapy discontinued ≥4 weeks prior to study treatment; absolute neutrophil count (ANC) ≥1500/ L; platelets ≥100,000/ L; creatinine ≤ 1.5x upper limit of normal (ULN) or calculated creatinine clearance ≥60mL/min/1.73m 2 ; total bilirubin ≤ 1.5x ULN; aspartate aminotransferase (AST) / alanine aminotransferase (ALT) ≤ 2.5x ULN or ≤ 5x ULN if documented liver metastases present; prothrombin time ≤1.5x ULN unless receiving therapeutic anticoagulation; serum magnesium and potassium levels within normal limits; negative pregnancy test, known infection with human immunodeficiency virus, hepatitis B or C, and no coexisting severe medical conditions. Patients with brain metastases were eligible if controlled on a stable dose ≤ 10mg prednisone equivalent units / day. Patients gave written informed consent according to federal and institutional guidelines before treatment, and the study was conducted in accordance with accordance with the principles of the Declaration of Helsinki and the accordance with International Conference on Harmonization Guideline for Good Clinical Practice.
Dosage and Drug Administration
CUDC-101 was supplied in individually sealed vials containing lyophilized CUDC-101, catheter with an inline sterile filter over 1-hour on days 1 to 5 of a 14-day cycle. Patients could continue to receive additional cycles until PD, unacceptable toxicity and / or withdrawal of subject consent.
Dose Escalation Design
This study utilized a standard 3+3 dose escalation design. From the starting dose of 75 mg/m 2 /day, which was 1/6 th of the highest non-significantly toxic dose (HNSTD) in rats (the most sensitive species), dose levels were increased by doubling at each cohort until new onset (not present at baseline) of Grade 2 toxicity was observed. Subsequent cohorts used a Modified Fibonacci dose escalation scheme. Three patients were treated at each dose level until the first instance of DLT in the first two cycles was observed, after which up to 6 evaluable subjects were treated at that dose level. If a second DLT was observed in up to 6 patients, the DLT dose level would have been reached and additional patients would be added to the previous lower dose level up to a total of 6 patients. The MTD was defined as the dose level immediately below the dose at which two or more patients experience a DLT in the first two cycles (28 days). DLT was defined as any grade 3 or 4 non-hematological toxicity (grade 3 nausea or vomiting treated with less than optimal antiemetic therapy; grade 3 diarrhea treated with less than optimal antidiarrheal therapy; grade 3 alopecia was not considered a DLT); thrombocytopenia <25,000/uL of any duration or < 50,000/uL with bleeding; Grade 4 neutropenia lasting longer than 5 days, or Grade 3 or worse neutropenia with fever greater than 101.3ºF
(38.5ºC) or Grade 3 or worse neutropenia with infection; and any treatment delay or dose hold for drug-induced toxicity occurring in the first 2 cycles. Toxicity was graded according to the NCI CTCAE (v 3.0).
Pretreatment and Follow-up Studies
Research. only, and only pre-dose at all other visits. A pre-study MUGA scan was required for all patients with any history of coronary artery disease, cardiomyopathy, congestive heart failure, or clinically significant arrhythmia; additional scans were required at Cycle 2 Day 1 and at the end of treatment for these patients. Laboratory tests (CBC and chemistry)
were performed on days 1-5 and 8 (cycles 1 -3 only) and on day 15 (all cycles).
Plasma and Urine Pharmacokinetic Sampling and Assay
In Cycle 1, blood samples (3 mL) were collected in heparinized tubes immediately pre- 
Results
Study population
Twenty-five patients were treated in 1 of 5 dose cohorts between August 2008 and April 2010. Demographic characteristics, prior treatment history, and cancer types for the study participants are provided in Table 1 . The study population included 11 males and 14 females with a median age of 60 years (range 37-79). Performance status ranged from ECOG 0 (4 patients, 16%) to ECOG 1 (21 patients, 84%). Eligible patients had stage IV solid tumors for which they had received at least 1 prior treatment. The most common tumor types were breast (n = 6; 24 %), head and neck (n = 4; 16 %), and lung (n = 4; 16 %). The total number of patients and median number of doses administered at each dose level, as well as the overall dose escalation scheme, are depicted in Table 2 .
The median number of doses administered per patient was 14 (range, 1 -34). Patients discontinued treatment for the following reasons: disease progression (n = 16), adverse event unrelated to study treatment (n = 2), Physician / Sponsor Decision (n = 3), treatment-related adverse event [n=3; pericarditis and pericardial effusion (n = 1), increased serum creatinine (n = 2)], and other (n = 1).
Safety
All 25 patients were included in the safety evaluation. Table 3 Grade 2 increased serum creatinine). One patient in the 300 mg/m 2 cohort discontinued treatment due to a serious AE (also a DLT) of Grade 4 pericarditis, which was considered possibly related to study treatment.
Non-Hematologic Toxicities
The principal toxicities experienced on CUDC-101 treatment were transient reversible nausea (24%), fatigue (24%), dry skin (16%), serum creatinine elevation (12%) and serum AST elevation (12%). The majority of these events were Grade 1 or 2 in severity.
Reversible elevation in serum creatinine levels was considered to be a DLT and 
Hematologic Toxicity
Patients treated with CUDC-101 did not experience clinically significant changes in ANC or platelet counts and there were no hematologic AEs of greater than Grade 2 severity.
Pharmacokinetics
Mean plasma pharmacokinetic (PK) parameters for CUDC-101 from each dose cohort as well as Day 1 and Day 5 AUC and C max values for each patient are shown in Table 4 and Figure This phase I study was performed to evaluate the safety and tolerability along with the PK profile of CUDC-101 when administered IV. Dose levels up to 275 mg/m 2 were well tolerated with the most frequent adverse events being dry skin/rash, nausea, fatigue, constipation, dyspnea, and pyrexia. The type and frequency of adverse events were comparable with those previously reported with administration of erlotinib or vorinostat. Four DLTs were reported in the study, one i at 275 mg/ m 2 and three at 300 mg/ m 2 dose levels. These DLTs included Grade 2 serum creatinine elevation (n=3), and pericarditis and pericardial effusion in one patient. These events occurred within 24
hours following the first dose of CUDC-101, were transient, did not appear to worsen with continued study treatment, and were managed in 2 patients by dose delay and reduction. There was no indication of acute or cumulative creatinine increases in other study patients. The etiology and clinical significance of these increased serum creatinine levels has not been determined. Dose limiting increase in creatinine levels has been a common laboratory adverse event reported with single agent HDAC inhibitors (Pharmaceuticals 2010; 3:2751-67). No significant changes in serum chemistry parameters including serum creatinine were noted in preclinical toxicology studies. In dog toxicology studies, the kidney was identified as a potential target organ (vacuolation of the proximal tubule epithelium). These findings occurred at 40 and 80 mg/kg/day dose levels and were dose-related in incidence and severity. Other than pericarditis observed in a single subject at the 300 mg/m2 dose level, no clinically significant, treatmentrelated cardiac events, ECG changes, or MUGA abnormalities were observed on this study. Analysis of pre-and post-CUDC-101 treatment skin biopsy samples were available from 16 patients and were analyzed by IHC for biomarkers of target modulation. DLT; dose-limiting toxicity * Patient whose dose was reduced to the next lowest dose for toxicity. ** 1 patient with Grade 2 blood creatinine increased. *** 2 patients with Grade 2 blood creatinine increased; 1 patient with Grade 4 pericarditis.
The MTD was determined to be 275 mg/m 2 . As noted in Table 6 .2-1, a total of 4 patients experienced a DLT, including Grade 2 blood creatinine increased in 3 patients and Grade 4 pericarditis in 1 patient. Dose limiting creatinine increases occurred within 24 hours following the first dose of CUDC-101, were transient and did not appear to worsen with continued study treatment, and were managed by dose delay and reduction for 2 patients. One patient was discontinued study after dose limiting creatinine increase.
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